Alliance for Multispecialty Research, LLC. | Newton, KS

Research site

(Unclaimed)

Location

700 Medical Center Dr Suite 110, Newton, Kansas, United States of America

Site insights

Top conditions

Top treatments

ABP-671

Orforglipron

Linaclotide

BW-00112

Systane

Retatrutide

LY3502970

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 33 total trials

Status recently updated

A Study in Patients with Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Not yet enrolling

Enrolling

Mixed Dyslipidemia

Drug: BW-00112

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine...

Active, not recruiting

Genital Herpes

Biological: BEXSERO

Biological: mRNA-1608

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety an...

Active, not recruiting

Cytomegalovirus Infection

Biological: mRNA-1647

Biological: Placebo

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling

COVID-19

SARS-CoV-2 Virus

Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose

Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Enrolling

Chikungunya Virus Infection

Biological: Placebo booster

Biological: CHIKV VLP vaccine booster

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare th...

Active, not recruiting

Gout

Other: Placebo

Drug: Allopurinol

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (UBRO MM)

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing,...

Enrolling

Migraine

Drug: Ubrogepant

Drug: Placebo for Ubrogepant

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo